Immunology

Chemomab touts study confirming CCL24 link to systemic sclerosis severity

Clinical-stage biotech Chemomab Therapeutics has announced the publication of a study highlighting that high serum CCL24 levels are linked to…

Century secures $60m in stock sale and buys preclinical cell therapy biotech

Century Therapeutics has acquired US-based Clade Therapeutics, which specialises in allogeneic cell therapies, to expand its pipeline of cancer and…

Eliem Therapeutics agrees to acquire Tenet

US-based Eliem Therapeutics has announced a definitive agreement for the acquisition of development-stage private biotechnology company Tenet Medicines. The acquisition…

Vertex joins pharma immunotherapy deal uptick with $4.9bn Alpine purchase

Vertex Pharmaceuticals has agreed to acquire biotech Alpine Immune Sciences for $4.9bn, joining the growing number of pharma spending big on…

FDA grants approval for Alexion’s NMOSD treatment

The US Food and Drug Administration (FDA) has approved Alexion, AstraZeneca Rare Disease’s Ultomiris (ravulizumab-cwvz) to treat adults with anti-aquaporin-4…

AbbVie signs agreement to acquire Landos Biopharma for $212.5m

AbbVie has entered a definitive agreement to acquire clinical-stage biopharmaceutical company Landos Biopharma for $212.5m. The strategic acquisition boosts AbbVie's…

Mirador launches with $400m to develop precision therapies

Mirador Therapeutics has announced its launch after securing more than $400m from leading life sciences investors. The US-based company will…

Capstan secures $175m Series B funds for CAR-T therapy

Capstan Therapeutics has secured $175m oversubscribed Series B financing to advance its lead in vivo chimeric antigen receptor T cell…

Alumis secures $259m to develop therapies for immune dysfunction

Alumis has secured $259m in a Series C funding round to progress the development of its clinical-stage pipeline of oral…

Shifting the paradigm – novel approaches to amyotrophic lateral sclerosis therapy

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a swiftly advancing, fatal neurodegenerative condition marked by muscle…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close